TABLE 2.

Summary of studies (n = 8) regarding P. aeruginosa bacteremia, reporting risk factors for transmission and acquisition of carbapenem-resistant P. aeruginosa, based on multivariate analyses^a

Studyc	Country	Study design	Hospital setting	No. of cases	Quality scoreb	Risk factors
						For what	Factor	OR estimate	95% CI	P value
Joo, 2011 (73)	South Korea	cc	mix	46	4	imp	Aminoglycoside use	3.60	1.39–7.31	0.025
							Urinary catheter	3.19	1.39–7.31	0.006
							Carbapenem use	2.87	1.26–6.56	0.012
							Fluoroquinolone use	2.54	1.08–5.96	0.033
Tumbarello, 2011 (74)	Italy	cc	mix	106	6	mr	Central venous catheter	17.99	6.45–50.09	<0.001
							Previous antibiotic therapy	2.79	1.10–7.07	0.03
							Corticosteroid use	2.73	1.06–7.00	0.03
Yang, 2011 (75)	South Korea	cc	pea	7	4	mr	Admission to ICU	6.82	1.3–35.8	0.023
Johnson, 2009 (76)	USA	rc	mix	113	7	mr	Hospital-acquired BSI	2.41	1.39–4.18	0.002
							Previous transplantation	2.38	1.51–3.76	<0.001
							Admission to ICU	2.04	1.15–3.63	0.015
Tam, 2007 (77)	USA	cc	mix	18	4	car	Additional wk of hospitalization	1.25	1.04–1.51	0.019
Falagas, 2006 (78)	Greece	cc	mix	16	4	mr	Carbapenem use	9.0	2.4–34.3	0.001
Kang, 2005 (79)	South Korea	rc	mix	28	6	imp	Carbapenem use	40.96	8.92–188.3	<0.001
							Fluoroquinolone use	5.60	1.64–19.11	0.006
							Invasive procedure within previous 72 h	4.51	1.56–13.04	0.005
El Amari, 2001 (80)	Switzerland	cc	mix	81	4	mr	Previous monotherapy (including imipenem)	2.5	1.3–4.8	0.006

^aOR, odds ratio; CI, confidence interval; cc case control; rc, retrospective cohort; mix, mixed; pea, pediatric general; imp, imipenem; mr, multiresistance, including carbapenems; car, carbapenem; BSI, bloodstream infection.

^bAccording to the Newcastle-Ottowa quality assessment scale.

^cStudies are reported by first author, year, and reference number.